News & Events

Preparing a marketing authorisation application for the European Union can be costly when documentation is incomplete, submission requirements are misunderstood or critical deadlines are approaching. Validation problems and repeated requests for clarification may disrupt planned regulatory milestones and delay market entry. With expert regulatory affairs support from Billev Pharma East, pharmaceutical and biotechnology companies can… View Article …

Is your medical device’s biological evaluation threatening your regulatory timeline? Missing evidence, poorly justified testing and late-stage documentation gaps can result in additional work, avoidable costs and difficult questions during conformity assessment. The longer these issues remain unresolved, the harder they can become to address without disrupting development plans. Manufacturers need a clear, risk-based approach… View Article …

Developing effective medical education programs is increasingly challenging for pharmaceutical companies managing complex evidence, competing Medical Affairs priorities and limited scientific resources. When learning needs are unclear or content development is delayed, educational initiatives can lose focus and place additional pressure on internal teams. To address these challenges, companies need to identify genuine healthcare professional… View Article …

For medical device and in vitro diagnostic manufacturers established outside the European Union, EU market entry can become difficult long before the first product is placed on the market. MDR and IVDR requirements affect technical documentation, conformity assessment procedures, device and economic operator registration and ongoing regulatory communication. One essential requirement is appointing an EU… View Article …

An unexpected impurity, incomplete safety data or a question about chemical exposure can disrupt a development programme just as a submission deadline approaches. For pharmaceutical, biotechnology and medical device companies, risk assessment in toxicology is often the step that determines whether an identified concern can be resolved using existing evidence or whether further investigation is… View Article …

Outsourcing pharmaceutical manufacturing gives companies access to specialist expertise and manufacturing capacity, but it also creates responsibilities that must be clearly defined and effectively controlled. When a GMP quality agreement does not accurately describe the responsibilities of the parties involved, quality decisions can be delayed, investigations can remain unresolved, and manufacturing changes may be implemented… View Article …

Pharmaceutical companies invest significant resources in understanding patient needs, yet managing patient-centric initiatives across multiple teams and stakeholders remains a major challenge. Without effective patient journey management, valuable findings can become disconnected from strategic priorities, leaving Medical Affairs, Market Access, and other functions working toward different objectives. A well-defined patient journey provides the context for… View Article …

For US pharmaceutical companies seeking EU marketing authorisation, meeting European regulatory requirements can be challenging. Even with a well-developed medicinal product and an established regulatory dossier, preparing an application that meets EU requirements demands specialized expertise, careful documentation management, and effective coordination throughout the submission process. Without sufficient European regulatory expertise, companies risk encountering incomplete… View Article …

Expanding a US pharmaceutical programme into Europe often starts with a practical question: is the current programme actually ready for an EU submission, or are there regulatory decisions that should be addressed first? For companies already investing in development, manufacturing and submission preparation, the cost of answering that question too late can be significant. Delayed… View Article …

Finding the right CMC advisor can become difficult when development timelines are tight, technical information is distributed across manufacturers, laboratories and internal teams, and decisions made today can affect the quality dossier later in the product lifecycle. Companies may have strong scientific expertise in-house, but still lack the capacity to coordinate CMC inputs, prepare submission-ready… View Article …

For biotech companies, Medical Affairs can become a pressure point long before a full internal function is in place. As clinical programmes advance, evidence expands and launch planning begins, teams may suddenly need scientific communication, stakeholder engagement, medical education and medical information capabilities at the same time. The right medical affairs consultant can help close… View Article …

A company may have extensive regulatory documentation in place and still not have a clear answer to a critical question: where does the current regulatory position fall short of what is actually required? Differences can exist between approved information, supporting documentation, implemented changes, authority commitments and current regulatory expectations. In this context, experienced regulatory affairs… View Article …

Rare disease companies bringing a new therapy to market face a distinct medical education challenge: awareness of the disease itself may still be limited. Healthcare professionals may encounter only a small number of affected patients, symptoms can overlap with more common conditions, and diagnosis may depend on recognising when specialist referral or further testing is… View Article …

In oncology, the educational challenge is rarely a lack of information. The greater problem is timing: new biomarkers, indications, combination regimens and treatment sequences can alter clinical questions faster than a conventional education plan can be updated. For pharmaceutical and biotech teams, oncology medical education therefore has to remain aligned with a treatment landscape that… View Article …

A veterinary PSMF may appear to be a documentation requirement, but preparing one that is complete, internally consistent and ready for regulatory scrutiny requires much more than filling predefined sections. Information must be collected from across the wider veterinary pharmacovigilance system, verified against current practice and presented in a way that clearly demonstrates how the… View Article …

Advanced therapy medicinal products (ATMPs) combine complex science with manufacturing processes that can continue to evolve throughout clinical development. For developers, the challenge is not only producing a consistent product, but building a quality strategy that can support changing process knowledge, analytical capability and future regulatory expectations. This is where experienced regulatory affairs consulting can… View Article …

For biotech companies developing innovative therapies, communication with regulatory authorities can influence key development decisions. Yet limited internal regulatory resources, complex scientific questions and evolving evidence can make these interactions difficult to prepare and manage. This is where experienced biotech regulatory consulting can provide valuable support. When regulatory questions are poorly framed, scientific positions are… View Article …

Pharmaceutical Medical Affairs teams are expected to deliver scientifically rigorous, relevant and engaging education while managing increasingly complex evidence, multiple stakeholders and demanding timelines. Yet when specialist expertise or additional capacity is needed, expanding the delivery structure does not always solve the problem. What teams often need is an experienced medical education specialist who can… View Article …